Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

ACIP Recommendations

The ACIP develops recommendations on how to use vaccines to control disease in the United States.

The Committee’s recommendations are forwarded to CDC’s Director for approval. Once the ACIP recommendations have been reviewed and approved by the CDC Director and the U.S. Department of Health and Human Services, they are published in CDC’s Morbidity and Mortality Weekly Report (MMWR). The MMWR publication represents the final and official CDC recommendations for immunization of the U.S. population.

Professional organizations that work with the ACIP to develop the annual childhood and adult schedules include the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), the American College of Obstetricians and Gynecologists (ACOG), and the American College of Physicians (ACP).

  • ACIP Recommendations
    Complete list of ACIP recommendations published in the MMWR.
  • Immunization Schedules
    Links to the childhood, adolescent, catch-up, and adult immunization schedules; plus vaccine recording and screening forms.

October 2018 Meeting Recommendations

ACIP approved the following recommendations by majority vote at its October 2018 meeting.

  • Use of hepatitis A vaccine in persons experiencing homelessness;
  • The 2019 adult immunization schedule, for adults 19 years of age and older; and
  • The 2019 child and adolescent immunization schedules, for children 18 years of age and younger.

These recommendations have been adopted by the CDC Director and will become official once published in MMWR.


June 2018 Meeting Recommendations

ACIP approved the following recommendations by majority vote at its June 2018 meeting:

  • Reaffirmed the seasonal influenza recommendations for the 2018-2019 influenza season
  • Anthrax vaccine use for post-exposure prophylaxis in a mass vaccination campaign, including:
    • The intramuscular route of administration may be used if the subcutaneous route of administration presents clinical, operational, or logistical challenges that may delay or prevent effective vaccination
    • Should there be an inadequate supply of anthrax vaccine available for post-exposure prophylaxis, either 2 full doses or 3 half doses of anthrax vaccine absorbed (AVA) may be used to expand vaccine coverage
    • In immunocompetent adults aged 18 through 65 years, antimicrobials given in conjunction with vaccine may be discontinued at 42 days after the first vaccine dose or 2 weeks after the last vaccine dose, whichever comes later

These recommendations have been adopted by the CDC Director and will become official once published in MMWR.

TOP